BRAF and melanoma: More importantly, inhibiting SREBP-1 through pharmacological intervention re-sensitized BRAF-mutant melanoma cells to BRAF inhibitor therapies, demonstrating that combinational SREBP-1 and BRAF inhibitors are more effective in targeting drug-resistant cells [85].